

Introducing Smart Codes

Pap with Age-Based Screening Protocols



Now ordering the tests that protect your female patients is **easier than ever**

A smart way to order tests

Smart Codes were designed with your patients in mind

Cervical cancer and sexually transmitted infection (STI) screening are an important part of keeping your female patients healthy. But selecting the right combination of test codes takes time and can be a burden on your practice. That's why Sonora Quest Laboratories created Smart Codes - test codes that use a patient's age to determine which combination of HPV and CT/NG testing should be performed along with Pap. These codes provide you with a new option for ordering tests in addition to our standard menu codes.

Our Smart Codes also take into consideration tests for patients whose risk factors are independent of age, but for whom you decide may need to be tested.

See "Which Smart Code is right for your patients?" on the next page to learn more about what tests are included in each test code.



Clinically directed

Consistent with ACOG recommendations to ensure patients are getting appropriate care¹⁻³



Easy

Automatically adapt to a patient's age



Efficient

Eliminate the need to search for - and enter - multiple test codes

Smart Codes **improve your office workflow**, giving you more time to focus on your patients

Which Smart Code is right for your patients?

There are 3 new codes to choose from based on your testing needs

91384

Age-Based

Pap with Age-Based Screening Protocols

Age	Pap	High-risk HPV mRNA	HPV Genotyping 16, 18/45	CT/NG
<21 years old (not guideline based)	✓	–	–	–
21 - 25 years old	✓	If Pap is ASC-US	–	✓
26 - 29 years old	✓	If Pap is ASC-US	–	–
30 - 65 years old	✓	✓	When Pap is negative and HPV is positive	–
>65 years old (Use for high risk, or insufficient/unknown prior screening history)	✓	✓	When Pap is negative and HPV is positive	–

91385

Age-Based +
CT/NG

Pap with Age-Based Screening, Plus CT/NG

- Offers the same age-based screening protocol as test code 91384

Adds CT/NG screening for all age groups

91386

Age-Based +
CT/NG/TV

Pap with Age-Based Screening, Plus CT/NG/T. vaginalis

- Offers the same age-based screening protocol as test codes 91384

Adds CT/NG and *T. vaginalis* screening for all age groups

CT/NG, *Chlamydia trachomatis*/*Neisseria gonorrhoeae*
TV, *Trichomonas vaginalis*

ACOG screening recommendations

Age-based recommendations for cervical cancer and select STI screening¹⁻³

Age	Pap*	High - risk HPV	HPV Genotyping	CT/NG
Under 21	Not recommended	Not recommended	Not recommended	Recommended every year among sexually active women, as age puts this group at greater risk
21 - 25	Recommended every 3 years	Recommended to be used as a "reflex test" only when Pap result is ASC-US	Not recommended	Recommended every year among sexually active women, as age puts this group at greater risk
26 - 29	Recommended every 3 years	Recommended to be used as a "reflex test" only when Pap result is ASC-US	Not recommended	Age is not a risk factor for this patient population; screening recommended only for patients at increase risk
30 - 65	Recommended co-testing (using Pap and HPV concurrently) every 5 years (preferred), or cytology alone every 3 years		Option to use as "reflex test" in co-tested patients whose Pap is negative and HPV result is positive	Age is not a risk factor for this patient population; screening recommended only for patients at increased risk
Over 65	Screening should be discontinued if patient has had adequate negative prior screening results** and no history of CIN 2+ Recommend continuing routine age-based screening for women with a history of CIN 2, CIN 3, or adenocarcinoma in situ for a total of 20 years after spontaneous regression of appropriate management of CIN 2, CIN 3, or adenocarcinoma in situ			Age is not a risk factor for this patient population; screening recommended only for patients at increased risk

CT/NG, *Chlamydia trachomatis*/*Neisseria gonorrhoeae*

* The age-based offerings, which are described in the above table, are based on ACOG recommendations and include image-guided Pap tests. The ACOG recommendations do not specify a particular type of Pap test. All testing recommended by ACOG is available at Sonora Quest Laboratories and may be ordered individually.

** Defined as 3 consecutive negative Paps or 2 consecutive negative co-tests within the past 10 years, with the most recent test occurring within the past 5 years.

Use Sonora Quest Laboratories' Smart Codes to easily ensure your female patients are getting the HPV and CT/NG screening recommended for their age

References: 1. The American Congress of Obstetricians and Gynecologists. Well-Woman Recommendations. <http://www.acog.org/About-ACOG/ACOG-Departments/Annual-Womens-Health-Care/Well-Woman-Recommendations>. Accessed January 26, 2016.
2. The American College of Obstetricians and Gynecologists. Practice bulletin 157: clinical management guidelines for obstetrician-gynecologists: cervical cancer screening and prevention. *Obstet Gynecol.* 2016; 127:e1-20 3. The American College of Obstetricians and Gynecologists. Practice bulletin 140: clinical management guidelines for obstetrician-gynecologists: management of abnormal cervical cancer screening test results and cervical cancer precursors. *Obstet Gynecol.* 2013;122(6): 1338-1367

Sonora Quest Laboratories, any associated logos, and all associated Sonora Quest Laboratories registered or unregistered trademarks are the property of Sonora Quest Laboratories. ©2016 Sonora Quest Laboratories. All rights reserved. 08/2016

